全身化疗腔内免疫序贯治疗肺癌合并胸腔积液临床研究

Clinical resrarch of malignant pleural effusion due to lung cancer by systemic chemotherapy combined with intrathoracic sequent immunotherapy

目的研究全身化疗腔内免疫序贯治疗肺癌胸腔积液的临床疗效及免疫指标变化。方法将45例肺癌合并胸腔积液患者随机分两组治疗,两组均予以GP方案化疗2个周期,化疗第15天尽量排净胸水。治疗组并胸腔内注射白介素-2,连续4次;对照组仅间断放胸水。观察两组治疗前后胸水中树突状细胞数量及治疗后胸水缓解率。结果治疗组临床有效率、胸水中树突状细胞数量均明显高于对照组(P<0.01)。结论全身化疗腔内免疫序贯治疗肺癌合并胸腔积液可增加患者免疫功能,提高临床疗效。

[Objective] To evaluate the clinical effectiveness and the changes of relative immune parameters in the treatment for the patients with malignant pleural effusion due to lung cancer by systemic chemotherapy combined with intrathoracic sequent immunotherapy. [Methods] 45 patients with malignant pleural effusion due to lung cancer were divided into two groups. They were given systemic chemotherapy （GP scheme,two period）. The pleural effusion was drained thoroughly before the 15th day, and then IL-2 were injected into pleural cavity of the patients in observed groups for four times,but the malignant pleural effusion were drained from the control group intermittently only. The number of dendritic cells in pleural effusion for all patients were investigate before and after therapy and the remission rate of pleural effusion of all patients was also observed after therapy. [Results] The effective rate and the number of of dendritic cells of pleural effusion in observed group were higher than those in control group （P〈 0. 01）. [Conclusion] Systemic chemotherapy combined with intrathoracic sequent immunotherapy can improve the immune function and the clinical effectiveness of patients.